GLG News by Ophthalmologists
Request a free trial
October 15, 2007
Innovative Preventive Pulmonary Therapy Offers Promise of Increased Longevity for Young Cystic Fibrosis Patients
Analysis of: Inspire Completes Enrollment in Phase 3 Cystic Fibrosis Trial | www.pipelinereview.com
Author: GLG Expert Contributor
Analysis of: Inspire Completes Enrollment in Phase 3 Cystic Fibrosis Trial | www.pipelinereview.com
Author: GLG Expert Contributor
Inspire Pharmaceuticals' founding concept is based upon P2Y2 receptor agonist technology, now approaching fruition with groundbreaking cystic fibrosis (CF) clinicals. Well tolerated three times daily nebulizer therapy with denufosol for young CF patients promises improved pulmonary function,...
September 24, 2007
OMEGA 3 FATTY ACIDS CAN HOLD PROMISE IN TREAMENT OF MANY EYE DISEASES
Analysis of: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth | www.pnas.org
Author: GLG Expert Contributor
Analysis of: IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth | www.pnas.org
Author: GLG Expert Contributor
Omega-3 supplementation could be a useful strategy for protecting against retinopathy of prematurity (ROP), say Swedish investigators. In the study, mice with retinopathy were fed food enriched with either omega-3 or omega-6. Mice that ate omega-3 initially lost fewer retinal blood vessels than mice...
September 24, 2007
HIGH BLOOD PRESSURE CASES RISING IN USA AND SO MAY GLAUCOMA
Analysis of: Blood Pressure, Arterial Stiffness, & Open Angle Glaucoma: The Rotterdam Study | archopht.ama-assn.org
Author: GLG Expert Contributor
Analysis of: Blood Pressure, Arterial Stiffness, & Open Angle Glaucoma: The Rotterdam Study | archopht.ama-assn.org
Author: GLG Expert Contributor
Patients with high arterial pulse pressure may be at increased risk for high-tension open angle glaucoma, a Dutch study concludes. Researchers analyzed data from 5,317 individuals, 215 of who had definite or probable open-angle glaucoma and 5,102 of whom were disease free.The analysis found that high-tension...
September 21, 2007
ALCON MOVING FORWARD QUICKLY WITH WAVELIGHT PURCHASE
Analysis of: Ophthalmic business: Alcon exceeds 70% stake in WaveLight | www.osnsupersite.com
Author: GLG Expert Contributor
Analysis of: Ophthalmic business: Alcon exceeds 70% stake in WaveLight | www.osnsupersite.com
Author: GLG Expert Contributor
Alcon holds more than 70% of Wavelights shares and its takeover of Wavelight has been approved by the German authorities. WHile wavelight produces some interesting intraocular lenses, it is clear that Alcons interest in Wavelight lies in its realiable and fast excimer laser system that can be used for...
September 21, 2007
NEW DIRECTIONS IN GLAUCOMA THERAPY/RESERACH FOR FUTURE
Analysis of: Targeting amyloid- b in Glaucoma | www.pnas.org
Author: GLG Expert Contributor
Analysis of: Targeting amyloid- b in Glaucoma | www.pnas.org
Author: GLG Expert Contributor
New research indicating the presence of amyloid-beta protein in dying retinal cells suggests a new direction in glaucoma research. Amyloid-beta is a protein found in Alzheimer's plaques. Using a rat model of glaucoma, the researchers found that the dying retinal cells
showed accumulation of amyloid-beta....
September 10, 2007
LX211 (LUX) could be a Blockbuster Drug in Uveitis Management.
Analysis of: Lux Granted Fast Track Designation by FDA for LX211 for the Treatment of Uveitis | pharmalive.com
Author: GLG Expert Contributor
Analysis of: Lux Granted Fast Track Designation by FDA for LX211 for the Treatment of Uveitis | pharmalive.com
Author: GLG Expert Contributor
LX211, calcineurin inhibitor and antiinflammatory drug, was granted Fast Track designation by the FDA. This move could expedite its approval for the management of non-infectious posterior, intermediate and panuveitis. In a field where there are few approved treatment modalities, this could be very big...
September 3, 2007
Is the recent Contact Lens Infection Outbreak the fault of AMO or Poor Hygiene?
Analysis of: AMO Says the Fault Lies With the Consumers--Not With Complete | westpalmbeach.injuryboard.com
Author: GLG Expert Contributor
Analysis of: AMO Says the Fault Lies With the Consumers--Not With Complete | westpalmbeach.injuryboard.com
Author: GLG Expert Contributor
This brief article describes the comments of the Advanced Medical Optics (AMO) President and CEO which deflect the blame of the recent contact lens infection on the consumer on poor contact lens hygiene. Although the comments of the AMO brass may be indeed true, there is not a single entity to...
August 31, 2007
athletes have always risked their health, eyes included
Analysis of: Aussie Boxing Champion Hospitalized Due To Eye Infection; Doubts About Career Prospects | www.allheadlinenews.com
Author: GLG Expert Contributor
Analysis of: Aussie Boxing Champion Hospitalized Due To Eye Infection; Doubts About Career Prospects | www.allheadlinenews.com
Author: GLG Expert Contributor
Boxer Sugar Ray Leonard had a complex retinal detachment, Orlando Brown of football was nearly blinded by a referee's thrown flag. Soft contact lens wear is barely compatible with sweaty, dusty contact sports. Some great basketball players wore (& wear) goggles. Asking boxers to wear...
August 31, 2007
Does Eyeonics have a long term future
Analysis of: Eyeonics Files For IPO | www.socaltech.com
Author: GLG Expert Contributor
Analysis of: Eyeonics Files For IPO | www.socaltech.com
Author: GLG Expert Contributor
It seems most likely that the reason that the major ophthalmic houses did not want the Crystalens-Eyeonics company is that the technology has substantial problems. Unlike the multifocal lenses, in order to give the best possible distance vision, near vision is not...
August 31, 2007
Biodem's (ASX:BDM) Subcutaneous Injection POTENTIAL Treatment for Diabetic Macular Edema.
Analysis of: BioDiem completes treatment in phase I/II study of eye drug BDM-E: Results due November 07 | www.pipelinereview.com
Author: GLG Expert Contributor
Analysis of: BioDiem completes treatment in phase I/II study of eye drug BDM-E: Results due November 07 | www.pipelinereview.com
Author: GLG Expert Contributor
Biodem (ASX:BDM) is conducting a a Phase I/II trail involving a 10 day course of subcutaneous injection of a peptide in the treatment of diabetic macular edema. The results of this trial which is being conducted abroad in Russia will be available in November 2007. Although promising...
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next51 to 60 of 158
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Why the doctor can't see you now
seattlepi.nwsource.com
Johnson & Johnson buys medical device maker
www.nytimes.com
Potassium loss from blood pressure drugs may explain higher risk of adult diabetes
www.fiercebiotech.com
McKesson Agrees To Settlement In Pricing Suits
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008

